Human CD20 (Full Length) Protein-VLP

概述

产品介绍

Cat No. CD20-PH1001

库存：现货

Size

点击咨询在线客服

产品介绍

内毒素

< 1.0 EU per μg of the protein as determined by the LAL method

生物活性

1.Immobilized Recombinant Human CD20 (Full Length) Protein-VLP (Cat: 11007-HNAH) at 5 μg/mL (100 μL/well) can bind Obinutuzumab, the EC₅₀ is 1.0-3.0 ng/mL.(Routinely tested)
2.Immobilized Recombinant Human CD20 (Full Length) Protein-VLP (Cat: 11007-HNAH) at 5 μg/mL (100 μL/well) can bind Ofatumumab, the EC₅₀ is 1.4-9.4 ng/ mL.(QC tested)
3.Immobilized Recombinant Human CD20 (Full Length) Protein-VLP (Cat: 11007-HNAH) at 5 μg/mL (100 μL/well) can bind Rituximab, the EC₅₀ is 6-18 ng/mL.(QC tested)
4.Immobilized Recombinant Human CD20 (Full Length) Protein-VLP from competitor A and SINO at 5 μg/mL (100 μL/well) can bind anti-CD20(Research grade Obinutuzumab biosimilar), the EC₅₀ is 3 ng/mL and 1.7 ng/mL, respectively. The results demonstrated that SINO CD20 (Cat. No. 11007-HNAH) has a higher binding capacity than that of competitor A (Routinely tested).
5.Immobilized Recombinant Human CD20 (Full Length) Protein-VLP from competitor A and SINO at 5 μg/mL (100 μL/well) can bind anti-CD20(Research grade Ofatumumab biosimilar), the EC₅₀ is 10.3 ng/mL and 5.4 ng/mL, respectively. The results demonstrated that SINO CD20 (Cat. No. 11007-HNAH) has a higher binding capacity than that of competitor A (Routinely tested).
5.Immobilized Recombinant Human CD20 (Full Length) Protein-VLP from competitor A and SINO at 5 μg/mL (100 μL/well) can bind anti-CD20(Research grade Rituximab biosimilar), the EC₅₀ is 19.8 ng/mL and 34.9 ng/mL, respectively. The results demonstrated that SINO CD20 (Cat. No. 11007-HNAH) has a higher binding capacity than that of competitor A (Routinely tested).

蛋白构建

A DNA sequence encoding the human CD20 (P11836) (Met1-Pro297) was expressed.

表达宿主

HEK293 Cells

种属

Human

预测 N 端

Met 1

分子量

The recombinant human CD20 predicts a molecular mass of 33.08 kDa.

缓冲液

Supplied as sterile solution 50mM HEPES, 150mM NaCl, 10% Trehalose, pH 7.2.
Please contact us for any concerns or special requirements.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

运输方式

It is supplied and shipped as liquid with dry ice.

稳定性 & 储存条件

Samples are stable for up to twelve months from date of receipt at -70℃. Store it under sterile conditions at -70℃ or lower. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Immobilized Recombinant Human CD20 (Full Length) Protein-VLP (Cat: 11007-HNAH) at 5 μg/mL (100 μL/well) can bind Obinutuzumab, the EC₅₀ is 1.0-3.0 ng/mL.(Routinely tested)

Immobilized Recombinant Human CD20 (Full Length) Protein-VLP (Cat: 11007-HNAH) at 5 μg/mL (100 μL/well) can bind Ofatumumab, the EC₅₀ is 1.4-9.4 ng/ mL.(QC tested)

Immobilized Recombinant Human CD20 (Full Length) Protein-VLP (Cat: 11007-HNAH) at 5 μg/mL (100 μL/well) can bind Rituximab, the EC₅₀ is 6-18 ng/mL.(QC tested)

Human CD20 (Full Length) Protein-VLP: 别称

B1 Protein, Human; Bp35 Protein, Human; CD20 Protein, Human; CVID5 Protein, Human; FMC7 Protein, Human; LEU-16 Protein, Human; S7 Protein, Human

CD20 背景信息

CD20 (membrane-spanning 4-domains, subfamily A, member 1), also known as MS4A1, is a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. CD20 / MS4A1 is expressed in all stages of B cell development except the first and last. CD20 / MS4A1 is present from pre-pre B cells through memory cells, but not on either pro-B cells or plasma cells. It is a B-lymphocyte surface molecule that plays a role in the development and differentiation of B-cells into plasma cells. CD20 / MS4A1may be involved in the regulation of B-cell activation and proliferation. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5(CVID5). CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections, and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells are usually in the normal range but can be very low.

全称

membrane-spanning 4-domains, subfamily A, member 1

研究领域

Cancer Drug Targets

参考文献

Tedder TF, et al. (1988) Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci. 85(1): 208-12.
Cragg MS, et al. (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 8: 140-74..
Polyak MJ, et al. (2003) A cholesterol-dependent CD20 epitope detected by the FMC7 antibody. Leukemia. 17(7): 1384-9.